ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
231.03
+0.38 (0.16%)
Aug 20, 2026, 10:00 AM EDT - Market open
ResMed Revenue
In the fiscal year ending June 30, 2026, ResMed had annual revenue of $5.65B with 9.85% growth. ResMed had revenue of $1.46B in the quarter ending June 30, 2026, with 8.58% growth.
Revenue (ttm)
$5.65B
Revenue Growth
+9.85%
P/S Ratio
5.89
Revenue / Employee
$497,225
Employees
11,370
Market Cap
33.33B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 5.65B | 507.12M | 9.85% |
| Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
| Jun 30, 2019 | 2.61B | 266.38M | 11.38% |
| Jun 30, 2018 | 2.34B | 273.46M | 13.23% |
| Jun 30, 2017 | 2.07B | 228.02M | 12.40% |
| Jun 30, 2016 | 1.84B | 159.80M | 9.52% |
| Jun 30, 2015 | 1.68B | 123.94M | 7.97% |
| Jun 30, 2014 | 1.55B | 40.52M | 2.68% |
| Jun 30, 2013 | 1.51B | 145.94M | 10.66% |
| Jun 30, 2012 | 1.37B | 125.37M | 10.08% |
| Jun 30, 2011 | 1.24B | 150.79M | 13.80% |
| Jun 30, 2010 | 1.09B | 171.62M | 18.64% |
| Jun 30, 2009 | 920.74M | 85.34M | 10.22% |
| Jun 30, 2008 | 835.40M | 119.07M | 16.62% |
| Jun 30, 2007 | 716.33M | 109.34M | 18.01% |
| Jun 30, 2006 | 607.00M | 181.49M | 42.65% |
| Jun 30, 2005 | 425.51M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Medline | 29.94B |
| Becton, Dickinson and Company | 22.48B |
| Baxter International | 11.47B |
| Alcon | 10.86B |
| Solventum | 8.31B |
| Avantor | 6.56B |
| The Cooper Companies | 4.23B |
| Align Technology | 4.14B |
RMD News
- 1 day ago - ResMed initiated with a Neutral at Rothschild & Co Redburn - TheFly
- 1 day ago - ResMed management to meet with KeyBanc - TheFly
- 2 days ago - Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor - GlobeNewsWire
- 12 days ago - ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat - Reuters
- 13 days ago - ResMed price target raised to $244 from $234 at RBC Capital - TheFly
- 13 days ago - ResMed price target lowered to $213 from $217 at Baird - TheFly
- 13 days ago - ResMed price target lowered to $215 from $225 at Wells Fargo - TheFly
- 13 days ago - ResMed price target lowered to $255 from $260 at KeyBanc - TheFly